tbuckley/cabot-search huggingface dataset:
Demographics and clinical characteristics of metastatic colorectal cancer patients treated with bevacizumab-awwb in real-world oncology clinics.
Authors: Richard DeClue, Whitney Rhodes, Neil A Accortt, Ran Jin, Darcie Sandschafer, Debra Wertz, Kashyap B. Patel
Journal: Journal of Clinical Oncology (2021)

90 Background: Bevacizumab-awwb is a biosimilar to bevacizumab approved by the FDA based on evidence obtained in a phase 3 study in non-squamous non-small cell lung cancer. The present real-world evidence study evaluated experience with bevacizumab-awwb (launched 07/19/2019) in patients with metastatic colorectal cancer (mCRC) in a real-world oncology setting to gain insight into biosimilar use for a bevacizumab-awwb approved indication lacking clinical trial data. Methods: This retrospective analysis identified patients, age ≥ 18 years (y), within existing medical records diagnosed with mCRC who initiated bevacizumab-awwb as first- or later-line treatment. Patients were identified from the ConcertAI Definitive Oncology Dataset, a consolidated EMR database of CancerLinQ and Vector Oncology, representing geographically diverse practice locations, including rural and urban centers, within the United States. Results: A total of 304 patients were eligible for this analysis. First use of bevacizumab-awwb in mCRC occurred within 20 days of product launch. Most patients (n = 262, 86%) were treated in a community setting and more than half of all eligible patients received prior bevacizumab (n = 162, 53%). Among 42 patients treated in academic settings 29 (69%) had not received bevacizumab prior to receiving bevacizumab-awwb. In the 162 patients with prior bevacizumab use, 134 (83%) had no recorded disease progression between the last bevacizumab infusion and start of bevacizumab-awwb. Among these 134 patients, 111 (83%) received bevacizumab-awwb within 28 days of last bevacizumab dose. Demographic and clinical characteristics of patients stratified by prior bevacizumab use were comparable (Table). In both subgroups most patients had an adenocarcinoma histological diagnosis with primary tumors in the rectum or sigmoid colon. Overall, most frequent comorbidities of mCRC patients were diabetes (24%), chronic obstructive pulmonary disease (10%), and renal disease (8%). Conclusions: Patients with mCRC who received bevacizumab-awwb in this real-world oncology setting in the first year post product launch were similar regardless of prior bevacizumab use. Among patients with prior bevacizumab use, 83% continued with bevacizumab-awwb in the same line. In the subset of patients without progression post bevacizumab, most received bevacizumab-awwb within 28 days of last bevacizumab dose demonstrating use of bevacizumab-awwb in new and continuing patients. [Table: see text]
Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery
Authors: Christopher P. Scally, Keith F. Fournier, Paul F. Mansfield
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Author Correction: Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes
Authors: Joel W. Blanchard, Michael Bula, Jose Davila-Velderrain, Leyla Anne Akay, Lena Zhu, Alexander Frank, Matheus B. Victor, Julia Maeve Bonner, Hansruedi Mathys, Yuan-Ta Lin, Tak Ko, David A. Bennett, Hugh P. Cam, Manolis Kellis, Li-Huei Tsai
Journal: Nature Medicine (2021)
Abstract 18958: High Pre-Operative Right Atrial Pressure to Pulmonary Capillary Wedge Pressure Ratio is Not Associated With Right Ventricular Dysfunction After LVAD Implantation
Authors: Rebecca J Cogswell, S. Carolina Masri
Journal: Circulation (2013)

Background: High RA pressure (RAP) to pulmonary capillary wedge pressure (PCWP) ratio has been associated with right ventricular (RV) failure after left ventricular assist device (LVAD) placement. This predictor has performed variably in external validation sets and RV failure after LVAD remains difficult to predict. We sought to determine the relationship between pre-operative RA:PCWP ratios and post-LVAD hemodynamic measures of RV function. Hypothesis: A high pre-operative RAP:PCWP ratio will be associated with RV dysfunction by invasive hemodynamics (high RAP, low cardiac index) after LVAD implantation. Methods: Right heart catheterization and other hemodynamic variables were collected both pre and post (within 48-72 hours) LVAD implantation on a cohort of 69 patients with end stage systolic heart failure. Patients were divided into 3 groups based on pre-operative RAP:PCWP ratios and pre and post-op hemodynamic data was analyzed by group. Results: Pulmonary vascular resistance (PVR) was higher and pulmonary artery capacitance (PAC) was lower in patients with the highest pre-operative RAP:PCWP ratios. There was no difference in post-LVAD RA pressure, cardiac index, or PCWP between RAP:PCWP groups (Table). In fact, higher pre-operative RAP to PCWP ratios were associated with the larger decreases in RA pressure post LVAD, with each 0.1 increase in pre-operative RAP:PCWP ratio being associated with a 1.7 mm Hg decrease in RA pressure post LVAD (p &lt; 0.0001). Conclusions: High pre-operative RAP:PCWP ratios were associated with the largest drop in RA pressure after LVAD implantation. While high RAP:PCWP ratios have previously been associated with RV failure, in the presence of increased RV afterload, this seemed to predict a favorable hemodynamics response and should not preclude LVAD implantation.
Abstract 14788: Association of Relative Ambient Temperature and LVAD-Associated Infection Rate
Authors: Pasquarello Dawn, Johana Fajardo, Kevin Welch, Vijay Chand, Leslie Gilbert, Lonnie Ennis, Clifford A Beach, Lucian Lozonschi, Thomas Disalvo, Ryan J Tedford, Brian A Houston
Journal: Circulation (2019)

Introduction: Infection rates in implantable defibrillators and pacemakers vary seasonally, with incidence positively associated with higher temperature. However, the impact of environmental factor...
Abstract 11276: Is the CHA2DS2-VASC Score a Predictor of Ischemic Stroke in Patients with Atrial Fibrillation Taking Oral Anticoagulation?
Authors: Yoshiyuki Hama, Marehiko Ueda, Hiroyuki Takano, Yoichi Kuwabara, Akira Miyazaki, Masato Yamanouchi, Junji Kanda, Issei Komuro, Yoshio Kobayashi
Journal: Circulation (2011)

Background: The CHA2DS2-VASc score [congestive heart failure, hypertension, age ≥75 (double), diabetes, stroke (double), vascular disease, age 65-74, and female gender] has been proposed to determi...
Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting: Should We Be Worried?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Robert A. Harrington, Robert M. Califf
Journal: Journal of the American College of Cardiology (2006)
FRI0038 Intramuscular methotrexate (im-mtx) in inflammatory rheumatic disease ? clinical and patient perspectives
Authors: G Burbage, R Gupta, K Lim
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Methotrexate is regarded as an effective and safe disease modifying drug (DMARD). The IM route of administration has been shown to have certain advantages over the oral route. There has been an increase use of IM-Mtx in our department in the last 2 years, leading to increased workload in the nurse-led monitoring clinics and cost. <h3>Objectives</h3> To review both the clinical and patient experiences with IM-Mtx, focusing on efficacy and side-effects as well as patient satisfaction. <h3>Methods</h3> Medical case-notes of 31 patients, identified from our database, were reviewed. The clinical diagnosis, previous drug therapies, reason for changing to IM-Mtx, efficacy and side-effects were noted. In addition, the patients were asked to complete a questionnaire, looking at patient satisfaction and preferred venue for injections (monitoring clinic or local doctor?s surgery). <h3>Results</h3> Our patient cohort was made up of 24 rheumatoid arthritis, 4 seronegative spondyloarthritis, 2 lupus and 1 undifferentiated connective tissue disease. The majority of patients has been on a previous DMARD, including 24 patients on oral Mtx. Reasons for changing to IM-Mtx therapy were as follows: side-effects in 11 patients, loss of efficacy in 12 patients and poor oral compliance in 8 patients. The median starting and maintenance doses were 10 mg weekly (range 5–17.5) and 15 mg weekly (range 10–17.5) respectively. In the period of study, 5 patients discontinued IM-Mtx; 2 because of side-effects, 1 developed multiple nodulosis, 1 did not attend for follow-up and 1 died from an unrelated cause. Median duration of therapy in the remaining 26 patients was 10 months (range 1–20). Significant improvement in disease activity, as measured by ESR and CRP, was seen after 3 months (p &lt; 0.01), with improvement maintained after 9 months (p &lt; 0.01) of IM-Mtx therapy. 24 of the 26 current patients completed the questionnaire. On a satisfaction scale of 1 to 5, the average rating was 4.2, indicating patients were either very or extremely satisfied with their IM-Mtx therapy. 14 patients preferred their injections in the monitoring clinic, 5 patients preferred their local doctor's surgery and 5 patients expressed no preferences. Only 3 patients stated that weekly clinic visits were inconvenient. <h3>Conclusion</h3> IM-Mtx was found to be effective and well tolerated. It should be considered as an alternative in patients intolerant to other DMARDs, including oral Mtx. Despite weekly clinic visits, patients were either very or extremely satisfied with their therapy. The cost and resource implications of continuing with this therapy need to be addressed.
Presynaptic Kv3 channels are required for fast and slow endocytosis of synaptic vesicles
Authors: Xin-Sheng Wu, Shobana Subramanian, Yalan Zhang, Bo Shi, Jessica Xia, Tiansheng Li, Xiaoli Guo, Lynda El-Hassar, Klara Szigeti-Buck, Jorge Henao-Mejia, Richard A. Flavell, Tamas L. Horvath, Elizabeth A. Jonas, Leonard K. Kaczmarek, Ling-Gang Wu
Journal: Neuron (2021)
A Crisis in the Marketplace: How Food Marketing Contributes to Childhood Obesity and What Can Be Done
Authors: Jennifer L. Harris, Jennifer L. Pomeranz, Tim Lobstein, Kelly D. Brownell
Journal: Annual Review of Public Health (2008)

Reducing food marketing to children has been proposed as one means for addressing the global crisis of childhood obesity, but significant social, legal, financial, and public perception barriers stand in the way. The scientific literature documents that food marketing to children is (a) massive; (b) expanding in number of venues (product placements, video games, the Internet, cell phones, etc.); (c) composed almost entirely of messages for nutrient-poor, calorie-dense foods; (d) having harmful effects; and (e) increasingly global and hence difficult to regulate by individual countries. The food industry, governmental bodies, and advocacy groups have proposed a variety of plans for altering the marketing landscape. This article reviews existing knowledge of the impact of marketing and addresses the value of various legal, legislative, regulatory, and industry-based approaches to change. *This PDF was amended on Aug. 5, 2009: See explanation at http://arjournals.annualreviews.org/doi/abs/10.1146/annurev.pu.30.090805.200009
Liver function abnormalities and mortality in patients with coronavirus disease 2019 (COVID-19)
Authors: L. S. Suarez, L. Simms, N. Dewaswala, K. Gupta, K. Dziadkowiec, P. Stawinski, S. Aboulenain, P. Torrres, H. Bhopalwala, F. R. Tuarez, J. Pino, K. De Almeida
Journal: Hepatology (2020)

Background: Coronavirus disease 2019 (COVID-19) has become a significant global health crisis with over 13,000,000 cases and 500,000 deaths worldwide over a span of months Meanwhile, predictors of clinical outcome remain elusive There has been increasing reports of liver dysfunction in COVID-19 Data on the importance of liver function test (LFT) abnormalities in COVID-19 is limited The aim of the study is to evaluate the predictive value of LFTs in predicting COVID-19 mortality Methods: This is a single center retrospective cohort study including 127 patients with laboratory-confirmed COVID-19 admitted from March 12 to April 5, 2020 Patients who did not have liver function tests done were excluded (n=31) The primary endpoint was all cause in-hospital mortality or discharge to hospice We characterized the LFTs of 96 patients with COVID-19 Univariate logistic regression was performed for total bilirubin, albumin, international normalized ratio (INR), alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) Multivariate logistic regression was performed for clinically significant predictors  Results: Of the 96 patients evaluated, the mean age was 63 ± 17 years old and 51% of which were females The mean MELD Score (Model for End-Stage Liver Disease) was 31 with a standard deviation of 10 Preexisting conditions included hypertension, diabetes and coronary artery disease in 54%, 20 4%, and 15 1% respectively None of the patients in the study had preexisting liver disease or cirrhosis In-hospital mortality or discharge to hospice occurred in 26% of patients In multivariable analysis of laboratory predictors, total bilirubin (p < 0 0001) was the most highly significant overall predictor of mortality followed by albumin (p= 0 009) and INR (p= 0 0442) ALP, ALT and AST were not statistically significant, as shown in table 1 Conclusion: Hyperbilirubinemia, hypoalbuminemia and elevated INR are strongly associated with mortality in COVID-19 Further research into the complex relationship between hepatic function in COVID-19 may improve both understanding of pathophysiology and the clinical care of COVID-19 patients
OP0080 A randomised clinical trial of three back muscle rehabilitation programs for chronic low back pain
Authors: L Danneels, G Vanderstraeten, D Cambier, E Witvrouw, H De Cuyper
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> The purpose of this study was to determine the efficacy (pain relief and functional outcome) and the effect on the cross-sectional area (CSA) of the lumbar multifidus in chronic low back pain patients (CLBP). <h3>Methods</h3> To achieve this goal, fifty-nine patients were randomised into a 10-week stabilisation training (group 1, N = 19), a 10-week stabilisation training combined with dynamic resistance training (group 2, N = 20) and a 10-week stabilisation training combined with dynamic-static resistance training (group 3, N = 20). Prior to and after 10 weeks of training, the multifidus CSA's, were derived from standard CT images at three different levels (upper endplate of L3 and upper and lower endplate of L4). Pain relief and functional outcome were evaluated. <h3>Results</h3> Comparing pre-post training, the CSA of the multifidus statistically increased in group 3 at all levels. In contrast, no statistical differences over time were found in group 1 and 2. Comparing the increases in CSA during the study, a statistical significant greater increase was observed in group 3 compared to group 1 and 2. After intervention, all groups showed a statistically significant reduction in pain and functional disability levels, without statistically significant difference among the three intervention groups. <h3>Conclusion</h3> The results of this study suggest that stabilisation exercises and dynamic intensive lumbar resistance training have no significant effect on the CSA of the lumbar multifidus in CLBP patients. The static holding component, between the concentric and eccentric phase was found to be critical in inducing muscle hypertrophy during the first 10 weeks. On the basis of the pain and disability improvements all of the treatments were equally beneficial.
Implementing Expanded Prenatal Genetic Testing: Should Parents Have Access to Any and All Fetal Genetic Information?
Authors: Michelle J. Bayefsky, Benjamin E. Berkman
Journal: The American Journal of Bioethics (2021)

Prenatal genetic testing is becoming available for an increasingly broad set of diseases, and it is only a matter of time before parents can choose to test for hundreds, if not thousands, of genetic conditions in their fetuses. Should access to certain kinds of fetal genetic information be limited, and if so, on what basis? We evaluate a range of considerations including reproductive autonomy, parental rights, disability rights, and the rights and interests of the fetus as a potential future child. We conclude that parents should be able to access information that could be useful during pregnancy, but that testing for non-medical information should be limited. Next, we argue that the government lacks a compelling state interest in regulating prenatal genetic testing and propose that regulation should occur through medical professional organizations. Finally, we present a framework for determining what testing physicians should recommend, offer neutrally, or not offer at all.
Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’’ by Zou<i>et al</i>
Authors: Jinjing Liu, Chan Zhao, Wenjie Zheng
Journal: Annals of the Rheumatic Diseases (2021)

Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou et al We thank Zou and colleagues for their interests and insightful comments 1 on our recently published work 2 and are impressed by the encouraging results of tofacitinib on patients with refractory Behçet's uveitis (BU).In this study, 5 mg two times per day tofacitinib was given to active patients with BU with prednisone reduced from 50 to 60 mg per day to 30 mg per day and withdrawal of conventional immunosuppressants (cyclosporine A or tacrolimus), which lead to treatment 'success' and 'flare' in 10 (76.9%) and 3 (23.1%) of the 13 included patients, respectively.Moreover, all the 10 patients responded to tofacitinib discontinued corticosteroid during a follow-up period between 24 and 38 months.This study provides preliminary evidence that tofacitinib might be a promising treatment for refractory BU.A minor disadvantage is that the authors did not evaluate the fundus based on a standard scoring system. 3hile there is evidence that Janus kinase (JAK)-mediated pathways are activated in active Behçet's syndrome (BS), 4 our study revealed that different phenotypes of BS responded variably to tofacitinib, which suggest that the role of tofacitinib in various BS phenotypes should be addressed individually due to the complexity and heterogeneity of BS. 2 Studies on intraocular inflammatory markers revealed significantly increased levels of interleukin (IL)-2, IL-8, IL-13, tumor necrosis factor α (TNFα), eotaxin and IL-1ra in aqueous humour samples from patients with BU. 5 Tofacitinib is a small molecule pan-JAK inhibitor, it is reasonable to infer that tofacitinib can cross the blood-ocular barriers easily to exert its anti-inflammatory effects in the eye by inhibiting multiple cytokine pathways.Several studies have reported the effectiveness of JAK inhibitors in treating non-infectious uveitis.In a mouse model of experimental autoimmune uveitis, tofacitinib significantly suppressed secretion of IFN-γ and development of disease. 6In a retrospective clinical study, juvenile idiopathic arthritis (JIA) cases refractory to at least two biological agents (including TNFα blockers, tocilizumab, rituximab and abatacept) responded to baricitinib 4 mg/day (n=3) and tofacitinib 10 mg/day (n=1). 7Tofacitinib was also reported to be effective in an adult JIA patient with anterior uveitis and macular edema, 8 a patient with scleritis and a patient with anterior and intermediate uveitis. 9urrently, a few ongoing clinical trials are evaluating the role of JAK inhibitors for non-infectious uveitis (NCT03580343, NCT04088409 and NCT03207815) but none exclusively addresses BU.Thus, future studies are expected to delineate the efficacy and safety profiles of different JAK inhibitors for refractory BU, which is indeed a devastating condition for both patients and physicians.
Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada
Authors: Sri Adapa, Olga Ovcinnikova, Ian Leighton, Shamika de Silva, Matthew Bending, Larisa Belyanskaya, Cosentino Lidia, Anne Myerson
Journal: Blood (2017)
Gastric cancer burden: Evidence from a safety-net hospital.
Authors: Arnold Forlemu, Dimas Kosa, Dawood Findakly, Surabhi Amar
Journal: Journal of Clinical Oncology (2021)

187 Background: Gastric cancer is a leading cause of cancer-related deaths worldwide, with more than eleven thousand estimated gastric cancer deaths expected to occur this 2020 in the United States (US). Understanding the burden and trends in gastric cancer across demographics and different locations in the US is crucial to develop effective preventive strategies. This study describes, characterizes, and identifies high risk group gastric cancer patients, who may benefit the most from preventive and management strategies. Methods: A retrospective study was conducted between 2010 to 2019 at our institution to identify patients diagnosed with gastric cancer during that period. Data on demographics, risk factors, mode of presentation, pathology, site, type, and stage of gastric cancer were obtained. Chi-square was used to compare categorical variables. Regression analysis was used to evaluate factors associated with late-stage disease and cancer type. Results: A total of 111 patients were analyzed in this study. The median age of gastric cancer patients was 52 years (range 27 to 87 years). Most of the patients were Hispanic (70.3%), non-citizens (59.5%), were uninsured (69.4%), and 67.6% were living below the federal poverty level (FPL). Also, 31.5% of the patients had a family history of cancer, had diffuse-type adenocarcinoma (61%), late-stage disease (76.6%), 52.4% of the cancers were in the distal portion of the stomach. Uninsured patients were more likely to die compared to insured patients, however, this difference was not statistically significant (64.9% vs 47.1%, p = 0.077). Age below 40, Hispanic ethnicity, being uninsured, and living below FPL were associated with higher rates of late-stage disease and diffuse-type cancer (p &lt; 0.05). Conclusions: Our data suggest a younger age at gastric cancer diagnosis than the national average. Moreover young, and uninsured Hispanics presented with advanced gastric cancer and may represent a high-risk target population for preventive strategies.